UNSPSC 51392608: Phenylpropanolamine bitartrate

This classification denotes an adrenergic agonist with the molecular formula C9H13NO.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B48FTC099P, chemically known as (r*,s*)-(+-)-alpha-(1-aminoethyl)benzenemethanol bitartrate but more generally known as phenylpropanolamine bitartrate, which bears US NIH Compound Identifier 62941. European Medicines Agency schedules Phenylpropanolamine bitartrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03781MIG.

UNSPSC 51392608 Phenylpropanolamine bitartrate is a Commodity code that in recent state and local procurement activity does not align with its nominal scope. The single recent opportunity posted under this code, Seminole County, Florida's IFB 60459723LAS, solicits naloxone and safe drug deactivation systems — pharmaceutical products and harm-reduction equipment unrelated to phenylpropanolamine bitartrate, a decongestant and appetite suppressant. The mismatch suggests either a tagging error in the county's procurement system or a significant divergence between the UNSPSC code definition and actual usage by this issuing body. State and local governments classifying pharmaceutical procurements do not consistently apply UNSPSC taxonomy correctly, and misclassified opportunities under this code should be treated with caution.

Seminole County, Florida is the sole issuing body with recent activity on record under this code. The county released IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract has an initial two-year term with a one-year renewal option. No other state or local jurisdictions show recent procurement activity under this code, and no additional opportunities are present in the source record. Firms pursuing state and local work in pharmaceutical procurement should monitor this code carefully for posting errors and cross-reference opportunities with the actual goods and services being solicited rather than relying on the nominal code scope alone.